Table II.
Clinicopathological factors and LVI in primary breast cancer (n=4652).
| LVI-negative | ||||||
|---|---|---|---|---|---|---|
|
|
||||||
| Variables | Category | LVI-positive | Low | High | Total | P-valuea |
| Menopausal status | Premenopausal | 1,066 (66.0) | 342 | 206 (12.8) | 1,614 | |
| Postmenopausal | 2,218 (73.3) | 574 | 234 (7.7) | 3,026 | <0.0001 | |
| Male | 9 (75.0) | 1 | 2 (16.7) | 12 | ||
| Tumor size | T1 | 2,589 (78.8) | 538 | 159 (4.8) | 3,286 | |
| T2 | 623 (51.7) | 342 | 240 (19.9) | 1,205 | <0.0001 | |
| T3, 4 | 54 (45.0) | 28 | 38 (31.7) | 120 | ||
| Number of Involved Nodes | 0 | 2,656 (81.9) | 486 | 100 (3.1) | 3,242 | |
| 1-3 | 528 (49.7) | 333 | 201 (18.9) | 1,062 | <0.0001 | |
| > 4 | 104 (30.8) | 92 | 141 (41.7) | 338 | ||
| Estrogen receptor | Negative | 597 (67.2) | 184 | 107 (12.0) | 888 | |
| Positive | 2,696 (71.6) | 733 | 335 (8.9) | 3,764 | 0.007 | |
| Progesterone receptor | Negative | 906 (69.7) | 243 | 150 (11.5) | 1,299 | |
| Positive | 2,387 (71.2) | 674 | 292 (8.7) | 3,353 | 0.01 | |
| HER2 | Negative | 2,918 (72.4) | 761 | 351 (8.7) | 4,030 | |
| Positive | 375 (60.3) | 156 | 91 (14.6) | 622 | <0.0001 | |
| p53 overexpression | Without | 2,693 (71.5) | 741 | 335 (8.9) | 3,769 | ≥ |
| With | 442 (63.1) | 160 | 99 (14.1) | 701 | <0.0001 | |
| Ki-67 | ≤20% | 1,501 (79.5) | 299 | 87 (4.6) | 1,887 | |
| 21–49% | 1,297 (64.1) | 469 | 256 (12.7) | 2,022 | <0.0001 | |
| ≥50% | 495 (66.6) | 149 | 99 (13.3) | 743 | ||
| Nuclear grade | 1 | 1,980 (80.3) | 360 | 126 (5.1) | 2,466 | |
| 2 | 615 (57.1) | 315 | 148 (13.7) | 1,078 | <0.0001 | |
| 3 | 698 (63.0) | 242 | 168 (15.2) | 1,108 | ||
| Total | 3,293 | 917 | 442 | 4,652 | ||
a
The P-value shows that there was a significant difference when the LVI negative group was compared to both the high and low positive groups. LVI, lymphovascular invasion; HER2, receptor tyrosine-protein kinase erbB-2.